Previous 10 | Next 10 |
home / stock / vivxf / vivxf news
X4 Pharmaceuticals Inc. (XFOR) is expected to report $-0.15 for Q4 2023 Li Ning Co., Ltd. ADR (LNNGY) is expected to report for Q4 2023 Xos Inc. (XOS) is expected to report $-2.4 for Q4 2023 PainReform Ltd. (PRFX) is expected to report for quarter end 2023-12-31 Muenchener Rueckve...
Regenicin Inc (RGIN) is expected to report for quarter end 2023-06-30 Grasim Industries Ltd. ADR (GRSXY) is expected to report for quarter end 2023-06-30 Mitsubishi Heavy Industries Ltd. (MHVYF) is expected to report for Q1 2024 Japan Tobacco Inc. ADR (JAPAY) is expected to report $0....
World Copper (WCUFF) is expected to report $-0.01 for Q2 2023 GlassBridge Enterprises Inc (GLAE) is expected to report for quarter end 2023-06-30 Paladin Energy Ltd (PALAF) is expected to report for Q4 2023 Andritz AG ADR (ADRZY) is expected to report for Q2 2023 Cincinnati Bancor...
2023-07-24 10:56:12 ET Avivagen Inc ( TSXV: VIV:CA ) on Monday announced two orders for OxC-beta. The company said one order, for 500kgs, is with a new customer for use within the sow market, while the second order, for 600kgs, involves 100kgs for immediate delivery and an add...
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, the...
2023-03-17 08:32:08 ET Avivagen press release ( OTCPK:VIVXF ): Q1 GAAP EPS of -C$0.01. Revenue of C$0.07M (-74.1% Y/Y). For further details see: Avivagen GAAP EPS of -$0.01, revenue of $0.07M
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health ...
-Publication showcases the cumulative understanding to-date of Avivagen’s product from both a scientific and real world application perspective -Product’s value and safety has been shown through use in many settings, under differing conditions and in millions of animals ...
Avivagen Inc. (TSXV:VIV) (“ Avivagen ” or the “ Company ”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting...
Avivagen press release ( OTCQB:VIVXF ): Q3 Comprehensive loss of C$1.90M Revenue of C$48.61K (-94.5% Y/Y). For further details see: Avivagen reports Q3 results
News, Short Squeeze, Breakout and More Instantly...
BowFlex Inc. (BFXXQ) is expected to report for Q4 2024 Leafbuyer Technologies Inc (LBUY) is expected to report for Q3 2024 Pacific Booker Minerals Inc (PBMLF) is expected to report for Q1 2025 BZAM Ltd Com (BZAMF) is expected to report for Q1 2024 MJ Holdings Inc (MJNE) is expecte...
Orbital Infrastructure Group Inc. (OIGBQ) is expected to report for Q1 2024 OFS Credit Company Inc. (OCCI) is expected to report for Q2 2024 KBC Groupe NV ADR (KBCSY) is expected to report for Q1 2024 Daikin Industries Ltd ADR (DKILY) is expected to report $0.11 for Q4 2024 Invita...
MJ Holdings Inc (MJNE) is expected to report for Q1 2024 Meritage Hospitality Group Inc. (MHGU) is expected to report $0.17 for Q1 2024 Fresnillo Plc (FNLPF) is expected to report for Q1 2024 Luna Innovations Incorporated (LUNA) is expected to report $-0.01 for Q1 2024 Cano Health...